Durvalumab Shows Promise in Advanced Head and Neck Cancer

A phase II trial found that the immune checkpoint inhibitor durvalumab has promising clinical activity and is well tolerated both as monotherapy and in combination with tremelimumab in patients with heavily pretreated recurrent or metastatic head and neck cancer, whose tumors are PD-L1 low or negative.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Tags: Head & Neck Cancer News Source Type: news